Zacks Investment Research upgraded shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) from a hold rating to a buy rating in a report released on Wednesday. Zacks Investment Research currently has $3.25 price objective on the biotechnology company’s stock.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Several other analysts have also weighed in on the company. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Caladrius Biosciences in a research note on Friday, November 10th. ValuEngine raised Caladrius Biosciences from a strong sell rating to a sell rating in a research note on Friday, September 1st.
Caladrius Biosciences (CLBS) traded up $0.43 during trading hours on Wednesday, reaching $3.50. The company had a trading volume of 274,819 shares, compared to its average volume of 43,249. Caladrius Biosciences has a fifty-two week low of $2.63 and a fifty-two week high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 96.80% and a negative net margin of 84.10%. equities analysts predict that Caladrius Biosciences will post -2.48 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Caladrius Biosciences, Inc. (CLBS) Upgraded at Zacks Investment Research” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/11/18/caladrius-biosciences-inc-clbs-upgraded-at-zacks-investment-research.html.
Hedge funds have recently made changes to their positions in the company. KCG Holdings Inc. boosted its stake in shares of Caladrius Biosciences by 74.6% during the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 15,501 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Caladrius Biosciences by 2.8% during the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after purchasing an additional 4,163 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Caladrius Biosciences by 34.3% during the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 24,900 shares in the last quarter. 6.36% of the stock is currently owned by hedge funds and other institutional investors.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.